Andy Kaempf

3.3k total citations
50 papers, 530 citations indexed

About

Andy Kaempf is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andy Kaempf has authored 50 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 15 papers in Genetics and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andy Kaempf's work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Andy Kaempf is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Andy Kaempf collaborates with scholars based in United States, India and Denmark. Andy Kaempf's co-authors include Motomi Mori, Zahi Mitri, Young Hwan Chang, Takahiro Tsujikawa, Julia Femel, Amanda W. Lund, Guillaume Thibault, Christopher P. Loo, Ryan S. Lane and Jeffrey Tyner and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andy Kaempf

43 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andy Kaempf United States 12 227 181 138 135 123 50 530
Dominika Hempel Poland 10 247 1.1× 202 1.1× 95 0.7× 64 0.5× 147 1.2× 20 580
Ju-Hee Bang South Korea 13 247 1.1× 127 0.7× 105 0.8× 64 0.5× 51 0.4× 17 380
Benjamin J. Gigliotti United States 7 188 0.8× 106 0.6× 93 0.7× 79 0.6× 77 0.6× 18 392
George Orphanos Greece 10 225 1.0× 107 0.6× 99 0.7× 73 0.5× 50 0.4× 18 440
Magnus Zethoven Australia 14 192 0.8× 213 1.2× 111 0.8× 59 0.4× 33 0.3× 21 501
Christopher Riley United States 8 177 0.8× 179 1.0× 117 0.8× 145 1.1× 51 0.4× 11 514
Abdo Abou-Slaybi United States 3 181 0.8× 174 1.0× 66 0.5× 61 0.5× 138 1.1× 6 423
Susan B. Ingersoll United States 8 144 0.6× 144 0.8× 55 0.4× 82 0.6× 60 0.5× 21 516
Xinhai Wan United States 9 208 0.9× 235 1.3× 185 1.3× 39 0.3× 63 0.5× 10 503

Countries citing papers authored by Andy Kaempf

Since Specialization
Citations

This map shows the geographic impact of Andy Kaempf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Kaempf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Kaempf more than expected).

Fields of papers citing papers by Andy Kaempf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Kaempf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Kaempf. The network helps show where Andy Kaempf may publish in the future.

Co-authorship network of co-authors of Andy Kaempf

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Kaempf. A scholar is included among the top collaborators of Andy Kaempf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Kaempf. Andy Kaempf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2025). A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia. Blood. 146(Supplement 1). 657–657.
2.
Lachowiez, Curtis A., Joshua F. Zeidner, D. Peters, et al.. (2024). Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML. Blood. 144(Supplement 1). 62–62.
3.
Yılmaz, Burçak, et al.. (2024). Genetic analysis of metastatic castration resistant prostate cancer patients treated with Lu-177 PSMA radioligand therapy.. Journal of Clinical Oncology. 42(16_suppl). e17063–e17063. 1 indexed citations
4.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2023). Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy. Blood Cancer Discovery. 4(6). 452–467. 12 indexed citations
5.
Kaempf, Andy, Jennifer M. Loftis, R. L. Woltjer, et al.. (2023). Role of platelet count in a murine stasis model of deep vein thrombosis. Platelets. 35(1). 2290916–2290916. 5 indexed citations
6.
7.
Dekker, Simone E., Emily C. Liang, Andy Kaempf, et al.. (2023). Pre-Transplant Measurable Residual Disease By Next-Generation Sequencing Is a Better Predictor of Relapse Compared to BCR-ABL PCR in Adult Patients with Ph+ Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. 29(2). S102–S103. 1 indexed citations
8.
Dekker, Simone E., Caner Saygin, Marc S. Schwartz, et al.. (2023). Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph+ Acute Lymphoblastic Leukemia. Blood. 142(Supplement 1). 6061–6061. 2 indexed citations
9.
Kaempf, Andy, Michael Pfeffer, Thomas G. DeLoughery, et al.. (2023). Comparison of bleeding and thrombotic outcomes in veno‐venous extracorporeal membrane oxygenation: Heparin versus bivalirudin. European Journal Of Haematology. 112(4). 566–576. 4 indexed citations
10.
Kurtz, Stephen E., Christopher A. Eide, Andy Kaempf, et al.. (2022). Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. Blood Advances. 6(10). 3062–3067. 6 indexed citations
11.
Mitri, Zahi, Nour Abuhadra, Shaun M. Goodyear, et al.. (2022). Impact of TP53 mutations in Triple Negative Breast Cancer. npj Precision Oncology. 6(1). 64–64. 21 indexed citations
12.
Romine, Kyle A., Tamilla Nechiporuk, Daniel Bottomly, et al.. (2021). Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. Blood Cancer Discovery. 2(5). 518–531. 22 indexed citations
13.
Borate, Uma, Andy Kaempf, Jessica Minnier, et al.. (2021). FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy. Blood. 138(Supplement 1). 1269–1269. 2 indexed citations
14.
Kaempf, Andy, et al.. (2021). Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. BMC Cancer. 21(1). 1150–1150. 2 indexed citations
15.
Shouse, Geoffrey, Andy Kaempf, Audrey M. Sigmund, et al.. (2021). Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. Blood. 138(Supplement 1). 529–529. 4 indexed citations
16.
Eide, Christopher A., Stephen E. Kurtz, Andy Kaempf, et al.. (2020). Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. 34(9). 2342–2353. 16 indexed citations
17.
18.
Lane, Ryan S., Julia Femel, Christopher P. Loo, et al.. (2018). IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. The Journal of Experimental Medicine. 215(12). 3057–3074. 126 indexed citations
19.
Kurtz, Stephen E., Sherif Abdelhamed, Monika A. Davare, et al.. (2018). Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 32(11). 2374–2387. 46 indexed citations
20.
Kurtz, Stephen E., Christopher A. Eide, Andy Kaempf, et al.. (2018). Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. 32(9). 2025–2028. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dominika Hempel Breakdown of academic impact, for papers by Ju-Hee Bang Breakdown of academic impact, for papers by Benjamin J. Gigliotti Breakdown of academic impact, for papers by George Orphanos Breakdown of academic impact, for papers by Magnus Zethoven Breakdown of academic impact, for papers by Christopher Riley Breakdown of academic impact, for papers by Abdo Abou-Slaybi Breakdown of academic impact, for papers by Susan B. Ingersoll Breakdown of academic impact, for papers by Xinhai Wan
Rankless by CCL
2026